<DOC>
	<DOC>NCT01006785</DOC>
	<brief_summary>The purposes of this study are : - to investigate the safety and clinical efficacy of sole therapy with DLBS1425 in suppressing disease-(tumour) progression in subjects with advanced/metastatic breast cancer; and - to determine the minimal effective and safe dose of DLBS1425 in the therapy of advanced/metastatic breast cancer</brief_summary>
	<brief_title>Efficacy and Safety of DLBS1425 in Subjects With Advanced/Metastatic Breast Cancer</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<criteria>Subjects diagnosed with Stage IIIB or IV breast cancer who have failed with or refuse to receive standard chemotherapies Subjects with the expression of ER/PR negative; or positive ER/PR expression but have failed with or refuse to receive hormonal therapy Either + or expression of HER2/neu gene ECOG status = 02 At least have 1 evaluable and measurable metastatic lesion as defined by RECIST criteria Adequate haematological, liver, and renal function At least 3 weeks has elapsed since prior chemotherapy, radiotherapy, biological/hormonal therapy At least 4 weeks has elapsed since surgical biopsy / major surgery Allergic to the trial product Any other disease state, including infections or uncontrolled illnesses that could interfere with trial participation or trial evaluation Concurrent herbal (alternative) medicine or food supplements suspected to have effect on cancer disease</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>October 2012</verification_date>
	<keyword>Breast Cancer</keyword>
	<keyword>DLBS 1425</keyword>
	<keyword>Cancer</keyword>
	<keyword>Advanced/Metastatic (Stage IIIB/IV) Breast Cancer</keyword>
</DOC>